Clinical trial
Multicenter Phase II Single Arm Open-label Study on the Feasibility, Safety and Efficacy of Combination of CHOP-21 Supplemented With Obinutuzumab and Ibrutinib in Untreated Young High Risk Diffuse Large B-cell Lymphoma (DLBCL) Patients.
NCT02670317 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter Phase II Single Arm Open-label Study on the Feasibility, Safety and Efficacy of Combination of CHOP-21 Supplemented With Obinutuzumab and Ibrutinib in Untreated Young High Risk Diffuse Large B-cell Lymphoma (DLBCL) Patients.
- Lead sponsor
- Fondazione Italiana Linfomi - ETS
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 30, 2016
- Completion date
- February 28, 2017
- Enrollment
- 1 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.